CHEK2^∗1100delC Mutation and Risk of Prostate Cancer

Table 3

Characteristics and results of various cancer studies.

Cancer Site	Case/control	Population	Country	OR/HR (95% CI)	value	Ref.
Breast	(459) 25,571/(179) 30,056	(Meta-analysis)		3.01 (2.53–3.58)		[32]
Breast	1,828/7,030	(Cases/controls)	UK, FI, NE, GE, RU	6.43 (4.33–9.56)	<0.0001	[33]
Breast	(120) 2,554/(37) 3,267	(Familial cases)	NE	4.30 (2.97–6.25)	<0.0001	[34]
Breast	3,882/8,609	(Cases/controls)	CA	2.6 (1.1–5.8)	0.05	[35]
Breast	75/300	(Cases/controls)	SW	2.5	0.26	[36]
Breast	708 bilateral + 1,395 unilateral	(Cases only)	US, DE	1.8 (0.6–5.4)		[37]
Breast	71/1,692	(Cases/controls)	NE	4.1 (1.2–14.3)	0.05	[38]
Breast	(0) 668	(Cases only)	MAL			[39]
Breast	1,101/4,665	(Cases/controls)	DE	1.2 (0.7–2.1)		[24]
		(Breast)		3.2 (1.0–9.9)
		(Colorectal)		1.6 (0.4–6.5)
Breast	161/153		US	NS		[40]
Breast	2,311/496	(Female cases/controls)	CA	6.65 (2.37–18.68)		[41]
			US	0.12 (0.02–0.89)
Breast	1,071/1,620		UK, NE, CA, US, GE	1.1% of controls versus 5.1% of cases	0.00000003	[42]
Breast	300/1,665		US	1% among cases versus 0.3% of controls	0.1	[43]
Breast	10,860/9,065	(Aggregate)	UK, NE, FI, GE, AU	2.34 (1.72–3.20)	0.0000001	[44]
Breast	(0) 493	(Cases only)	KO			[45]
Breast	903/1,016		IR	0.5% of cases versus 0.1% of controls; 5.65 (0.66–48.46)	0.09	[46]
Breast	1,479	(Cases only)	US	2.1 (1.0–4.3)	0.049	[47]
Breast	1,035/1,885	(Positive family history)	FI	2.27 (1.11–4.63)	0.021	[48]
		(Bilateral)		6 (1.87–20.32)	0.007
Breast	300	(Cases only)	AU	0.6% of cases		[49]
Breast	237/331	(Cases/controls)	NE	11.4% of cases versus 2.8% of controls	0.001	[50]
Breast	302	(Cases only)	RU	3% of cases.		[51]
Breast	(0) 400/(0) 400		SP			[52]
Breast	(0) 196/(0) 1,024		CHL			[53]
Breast	(0) 102	(Familial cases)	US			[54]
Breast	507/513	(Cases/controls)	FR	1.14% in cases versus 0.29% in controls; 5.18	0.004	[55]
Breast	5,953	(Cases only)	PL	3.6 (2.1–6.2)	0.0001	[56]
		(Prostate)		4.4 (2.2–8.7)	0.0001
		(Colon)		4.2 (2.4–7.8)	0.0001
Breast	8,612	(Cases only)	UK			[57]
Breast, Colorectal	75	(Cases only)	SW	2.5%	0.26	[36]
Breast	(3) 1,434	(Cases only)	NE	3.4 (0.4–32.6)	0.3	[58]
Melanoma	(15) 1,889/(59) 12,801	(Combined)		1.79 (1.02–3.17)		[59]
			DE	2.01 (1.03–3.91)
			GE	1.42 (0.46–4.31)
Melanoma	(18) 2,619/(67) 17,481	(Meta-analysis)		1.81 (1.07–3.05)		[59]
Colorectal	(8) 818/(5) 760	(Unselected)	SW	1.49 (0.49–4.58)	0.48	[60]
	(2) 174/(5) 760	(Familial)		1.76 (0.34–9.13)	0.50
Colorectal	369	(Cases only)	NE	4.2% HNPCC cases		[61]
Colorectal	4,194/10,010	(Meta-analysis)		2.11 (1.41–3.16)	0.0003	[62]
	1,050/3,784	(Familial)		2.80 (1.74–4.51)	<0.0001
	652/2,115	(Sporadic)		1.45 (0.49–4.30)	0.50
Colorectal	(0) 210/(0) 446	(Cases/controls)	TUK			[16]
Esophagus	(8) 551/(9) 644	(Cases/controls)	NE	1.04 (0.35–3.06)	0.94	[63]
Head & Neck	(0) 91	(Case only)	GE			[64]
Ovary	(2) 268/(1) 821	(Cases/controls)	RU	6.17 (0.56–68.3)	0.09	[65]
Pancreas	(0) 270/(0) 683	(Cases/controls)	CZ			[66]
Leukemia	(8) 973/(18) 1,620	(Cases/controls)	UK	0.74 (0.32–1.7)		[67]
Lung	(0) 457	(Cases only)	NE			[58]
Brain	(0) 79	(Familial cases)	FR			[68]

UK: United Kingdom, FI: Finland, NE: Netherlands, GE: Germany, RU: Russia, CA: Canada, SW: Sweden, US: United States, DE: Denmark, GE: Germany, MAL: Malaysia, AU: Australia, KO: Korea, IR: Ireland, SP: Spain, CHL: Chile, FR: France, PL: Poland, TUK: Turkey, and CZ: Czech.